2024 Australia–New Zealand Expert Consensus Statement on Cardiac Amyloidosis

Nicole K Bart; Diane Fatkin; James Gunton; James L Hare; Dariusz Korczyk; Fiona Kwok; Kaitlyn Lam; David Russell; Hasib Sidiqi; Tim Sutton; Simon D J Gibbs; Peter Mollee; Liza Thomas

doi:10.1016/j.hlc.2023.11.027

2024 Australia–New Zealand Expert Consensus Statement on Cardiac Amyloidosis

Nicole K Bart, Diane Fatkin, James Gunton, James L Hare, Dariusz Korczyk, Fiona Kwok, Kaitlyn Lam, David Russell, Hasib Sidiqi, Tim Sutton, Simon D J Gibbs, Peter Mollee, Liza Thomas

Research output: Contribution to journal › Article › peer-review

1 Citation (Scopus)

22 Downloads (Pure)

Abstract

Over the past 5 years, early diagnosis of and new treatments for cardiac amyloidosis (CA) have emerged that hold promise for early intervention. These include non-invasive diagnostic tests and disease modifying therapies. Recently, CA has been one of the first types of cardiomyopathy to be treated with gene editing techniques. Although these therapies are not yet widely available to patients in Australia and New Zealand, this may change in the near future. Given the rapid pace with which this field is evolving, it is important to view these advances within the Australian and New Zealand context. This Consensus Statement aims to update the Australian and New Zealand general physician and cardiologist with regards to the diagnosis, investigations, and management of CA.

Original language	English
Pages (from-to)	420-442
Number of pages	23
Journal	Heart Lung and Circulation
Volume	33
Issue number	4
DOIs	https://doi.org/10.1016/j.hlc.2023.11.027
Publication status	Published - Apr 2024
Externally published	Yes

Keywords

Amyloidosis
Cardiac
Genetics
Heart failure
Heart failure with preserved ejection fraction
Hereditary
Transthyretin

Access to Document

10.1016/j.hlc.2023.11.027Licence: CC BY

Final published versionFinal published version, 2.45 MBLicence: CC BY

Cite this

@article{356213977b404827954b20c43b6490be,

title = "2024 Australia–New Zealand Expert Consensus Statement on Cardiac Amyloidosis",

abstract = "Over the past 5 years, early diagnosis of and new treatments for cardiac amyloidosis (CA) have emerged that hold promise for early intervention. These include non-invasive diagnostic tests and disease modifying therapies. Recently, CA has been one of the first types of cardiomyopathy to be treated with gene editing techniques. Although these therapies are not yet widely available to patients in Australia and New Zealand, this may change in the near future. Given the rapid pace with which this field is evolving, it is important to view these advances within the Australian and New Zealand context. This Consensus Statement aims to update the Australian and New Zealand general physician and cardiologist with regards to the diagnosis, investigations, and management of CA.",

keywords = "Amyloidosis, Cardiac, Genetics, Heart failure, Heart failure with preserved ejection fraction, Hereditary, Transthyretin",

author = "Bart, {Nicole K} and Diane Fatkin and James Gunton and Hare, {James L} and Dariusz Korczyk and Fiona Kwok and Kaitlyn Lam and David Russell and Hasib Sidiqi and Tim Sutton and Gibbs, {Simon D J} and Peter Mollee and Liza Thomas",

year = "2024",

month = apr,

doi = "10.1016/j.hlc.2023.11.027",

language = "English",

volume = "33",

pages = "420--442",

journal = "Heart Lung and Circulation",

issn = "1443-9506",

publisher = "Elsevier Australia",

number = "4",

}

TY - JOUR

T1 - 2024 Australia–New Zealand Expert Consensus Statement on Cardiac Amyloidosis

AU - Bart, Nicole K

AU - Fatkin, Diane

AU - Gunton, James

AU - Hare, James L

AU - Korczyk, Dariusz

AU - Kwok, Fiona

AU - Lam, Kaitlyn

AU - Russell, David

AU - Sidiqi, Hasib

AU - Sutton, Tim

AU - Gibbs, Simon D J

AU - Mollee, Peter

AU - Thomas, Liza

PY - 2024/4

Y1 - 2024/4

N2 - Over the past 5 years, early diagnosis of and new treatments for cardiac amyloidosis (CA) have emerged that hold promise for early intervention. These include non-invasive diagnostic tests and disease modifying therapies. Recently, CA has been one of the first types of cardiomyopathy to be treated with gene editing techniques. Although these therapies are not yet widely available to patients in Australia and New Zealand, this may change in the near future. Given the rapid pace with which this field is evolving, it is important to view these advances within the Australian and New Zealand context. This Consensus Statement aims to update the Australian and New Zealand general physician and cardiologist with regards to the diagnosis, investigations, and management of CA.

AB - Over the past 5 years, early diagnosis of and new treatments for cardiac amyloidosis (CA) have emerged that hold promise for early intervention. These include non-invasive diagnostic tests and disease modifying therapies. Recently, CA has been one of the first types of cardiomyopathy to be treated with gene editing techniques. Although these therapies are not yet widely available to patients in Australia and New Zealand, this may change in the near future. Given the rapid pace with which this field is evolving, it is important to view these advances within the Australian and New Zealand context. This Consensus Statement aims to update the Australian and New Zealand general physician and cardiologist with regards to the diagnosis, investigations, and management of CA.

KW - Amyloidosis

KW - Cardiac

KW - Genetics

KW - Heart failure

KW - Heart failure with preserved ejection fraction

KW - Hereditary

KW - Transthyretin

UR - http://www.scopus.com/inward/record.url?scp=85189511260&partnerID=8YFLogxK

U2 - 10.1016/j.hlc.2023.11.027

DO - 10.1016/j.hlc.2023.11.027

M3 - Article

C2 - 38570258

AN - SCOPUS:85189511260

SN - 1443-9506

VL - 33

SP - 420

EP - 442

JO - Heart Lung and Circulation

JF - Heart Lung and Circulation

IS - 4

ER -

2024 Australia–New Zealand Expert Consensus Statement on Cardiac Amyloidosis

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this